Bibliographic Details
| Title: |
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer |
| Authors: |
Lang, I.1 lang@oncol.hu, Inbar, M.J.2, Kahán, Z.3, Greil, R.4, Beslija, S.5, Stemmer, S.M.6, Kaufman, B.7, Zvirbule, Z.8, Steger, G.G.9, Messinger, D.10, Brodowicz, T.9,11, Zielinski, C.9,11 |
| Source: |
European Journal of Cancer. Nov2012, Vol. 48 Issue 17, p3140-3149. 10p. |
| Database: |
Academic Search Ultimate |
